{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:04:48Z","timestamp":1787497488825,"version":"build-2736575974"},"reference-count":142,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Psoriatic arthritis (PsA) is a systemic inflammatory condition characterised by multiple clinical manifestations. Over the last decade, significant progress has been made in understanding the pathobiology of the disease. An expanded set of targeted therapies have emerged and have shown efficacy in PsA. Nevertheless, there is still a substantial subset of patients who experience no response or only a partial response to currently licensed therapies. The heterogeneous nature of the disease, together with a varying level of severity at presentation and disease activity during follow-up, brings tremendous challenges to devising management strategies. While there are certain pathophysiological similarities between PsA and rheumatoid arthritis (RA), it has become clear that there are discriminating features between these two conditions at the clinical, cellular, and molecular levels. However, there is a degree of overlap in the clinical approach when treating both PsA and RA, given that many biological and targeted therapies have proven efficacy for both pathologies. With an increasing understanding of the relevance of the IL-23\/IL-17 axis in PsA, pharmacological agents blocking this pathway have provided promising possibilities for patients with PsA.<\/jats:p>","DOI":"10.3390\/ijms24076384","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T02:03:53Z","timestamp":1680055433000},"page":"6384","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Targeted Therapies in Psoriatic Arthritis\u2014An Update"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1318-5820","authenticated-orcid":false,"given":"Sonia","family":"Sundanum","sequence":"first","affiliation":[{"name":"Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, D04 V1W8 Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Orr","sequence":"additional","affiliation":[{"name":"Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, D04 V1W8 Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Veale","sequence":"additional","affiliation":[{"name":"Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, D04 V1W8 Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semarthrit.2018.01.003","article-title":"Prevalence and incidence of psoriatic arthritis: A systematic review and meta-analysis","volume":"48","author":"Scotti","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"681172","DOI":"10.3389\/fmed.2021.681172","article-title":"Psoriasis to Psoriatic Arthritis: The Application of Proteomics Technologies","volume":"8","author":"Qi","year":"2021","journal-title":"Front. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic Arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/rheumatology\/keg384","article-title":"A prospective, clinical and radiological study of early psoriatic arthritis: An early synovitis clinic experience","volume":"42","author":"Kane","year":"2003","journal-title":"Rheumatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","article-title":"Diagnostic delay of more than 6\u2005months contributes to poor radiographic and functional outcome in psoriatic arthritis","volume":"74","author":"Haroon","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40744-016-0029-z","article-title":"Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey","volume":"3","author":"Kavanaugh","year":"2016","journal-title":"Rheumatol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"101693","DOI":"10.1016\/j.berh.2021.101693","article-title":"Unmet needs in psoriatic arthritis","volume":"35","author":"Ng","year":"2021","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1136\/ard.53.7.450","article-title":"Immunohistochemical markers for arthritis in psoriasis","volume":"53","author":"Veale","year":"1994","journal-title":"Ann. Rheum. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/art.1780360705","article-title":"Reduced synovial membrane macrophage numbers, elam-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis","volume":"36","author":"Veale","year":"1993","journal-title":"Arthritis Rheum."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1136\/ard.2005.050963","article-title":"Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: Implications for treatment","volume":"65","author":"Smeets","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/BOR.0000000000000069","article-title":"The interleukin-23\/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis","volume":"26","author":"Yeremenko","year":"2014","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.semarthrit.2016.05.012","article-title":"Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?","volume":"46","author":"Coates","year":"2016","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2340\/00015555-1833","article-title":"Current concepts in psoriatic arthritis: Pathogenesis and management","volume":"94","author":"Gottlieb","year":"2014","journal-title":"Acta Derm. Venereol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/nm.2854","article-title":"Primed for inflammation: Enthesis-resident T cells","volume":"18","author":"Lories","year":"2012","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e000025","DOI":"10.1136\/rmdopen-2014-000025","article-title":"What makes psoriatic and rheumatoid arthritis so different?","volume":"1","author":"Veale","year":"2015","journal-title":"RMD Open"},{"key":"ref_18","first-page":"S818","article-title":"Rituximab in psoriatic arthritis provides modest clinical improvement and reduces expression of inflammatory biomarkers in skin lesions","volume":"62","author":"Mease","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/1529-0131(199907)42:7<1481::AID-ANR23>3.0.CO;2-E","article-title":"Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis","volume":"42","author":"Reece","year":"1999","journal-title":"Arthritis Rheum."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"ii26","DOI":"10.1136\/ard.2004.031740","article-title":"Immunopathology of psoriasis and psoriatic arthritis","volume":"64","author":"Veale","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(97)12004-9","article-title":"Classification of inflammatory arthritis by enthesitis","volume":"352","author":"McGonagle","year":"1998","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+ CD4\u2212 CD8\u2212 entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1136\/ard.2008.089367","article-title":"Familial aggregation of psoriatic arthritis","volume":"68","author":"Chandran","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1136\/annrheumdis-2014-205461","article-title":"Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype","volume":"75","author":"Haroon","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1136\/ard.2007.073932","article-title":"Environmental risk factors for the development of psoriatic arthritis: Results from a case\u2013control study","volume":"67","author":"Pattison","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/S0140-6736(18)30949-8","article-title":"Clinical management of psoriatic arthritis","volume":"391","author":"Coates","year":"2018","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/rheumatology\/key173","article-title":"Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: Open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis","volume":"57","author":"Genovese","year":"2018","journal-title":"Rheumatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/art.40579","article-title":"Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate","volume":"70","author":"Mease","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jdcr.2019.08.015","article-title":"Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis","volume":"5","author":"Thibodeaux","year":"2019","journal-title":"JAAD Case Rep."},{"key":"ref_32","unstructured":"Research, J., and Development, L. (2022, December 13). A Study of Guselkumab and Golimumab Combination Therapy in Participants with Active Psoriatic Arthritis, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT05071664."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3899\/jrheum.190677","article-title":"Prevalence of Psoriatic Arthritis Patients Achieving Minimal Disease Activity in Real-world Studies and Randomized Clinical Trials: Systematic Review with Metaanalysis","volume":"47","author":"Saldanha","year":"2020","journal-title":"J. Rheumatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor \u03b1 antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four\u2013week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.40851","article-title":"Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/art.30223","article-title":"Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: A randomized, double-blind trial","volume":"63","author":"Braun","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"Kivitz","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"Dijkmans","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study","volume":"73","author":"Braun","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2217\/ijr.15.52","article-title":"Therapeutic targets in psoriatic arthritis","volume":"10","author":"Orr","year":"2015","journal-title":"Int. J. Clin. Rheumatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3899\/jrheum.140173","article-title":"Bone Formation in Psoriatic Arthritis: A Report from the GRAPPA 2013 Annual Meeting","volume":"41","author":"Schett","year":"2014","journal-title":"J. Rheumatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/BOR.0000000000000232","article-title":"Bone remodeling in psoriasis and psoriatic arthritis: An update","volume":"28","author":"Paine","year":"2016","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1172\/JCI200316069","article-title":"Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis","volume":"111","author":"Ritchlin","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nrrheum.2012.153","article-title":"Bone erosion in rheumatoid arthritis: Mechanisms, diagnosis and treatment","volume":"8","author":"Schett","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.rdc.2012.08.003","article-title":"Pathophysiology of new bone formation and ankylosis in spondyloarthritis","volume":"38","author":"Lories","year":"2012","journal-title":"Rheum. Dis. Clin."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/17512433.2017.1329009","article-title":"Tumor necrosis factor inhibitors in psoriatic arthritis","volume":"10","author":"Mantravadi","year":"2017","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_52","first-page":"S115","article-title":"Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis","volume":"33","author":"Johnsson","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","article-title":"Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/annrheumdis-2013-204934","article-title":"Is there a need for new agents with novel mechanisms of action in psoriatic arthritis?","volume":"73","author":"Orr","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1084\/jem.20061775","article-title":"Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction","volume":"203","author":"Sato","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_59","first-page":"ii61","article-title":"Psoriatic arthritis imaging: A review of scoring methods","volume":"64","author":"Sharp","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","article-title":"Ustekinumab for the treatment of patients with active ankylosing spondylitis: Results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)","volume":"73","author":"Poddubnyy","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1084\/jem.20030896","article-title":"Divergent pro-and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation","volume":"198","author":"Murphy","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/rheumatology\/keab461","article-title":"Interleukin-23 in perspective","volume":"60","author":"Sherlock","year":"2021","journal-title":"Rheumatology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo-and active comparator\u2013controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo-and active comparator\u2013controlled voyage 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: Results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): A double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): A double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/art.41553","article-title":"Efficacy and safety of guselkumab, an interleukin-23p19\u2013specific monoclonal antibody, through one year in biologic-naive patients with psoriatic arthritis","volume":"73","author":"McInnes","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e001457","DOI":"10.1136\/rmdopen-2020-001457","article-title":"Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-na\u00efve or TNF\u03b1 inhibitor-experienced","volume":"7","author":"Ritchlin","year":"2021","journal-title":"RMD Open"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.3899\/jrheum.201532","article-title":"Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis","volume":"48","author":"Rahman","year":"2021","journal-title":"J. Rheumatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1093\/rheumatology\/keab285","article-title":"Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies","volume":"60","author":"McGonagle","year":"2021","journal-title":"Rheumatology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: Results through one year of a phase IIIb, randomised, controlled study (COSMOS)","volume":"81","author":"Coates","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/art.42010","article-title":"Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two\u2009Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis","volume":"74","author":"McInnes","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: Results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3389\/fimmu.2018.01550","article-title":"The initiation, but not the persistence, of experimental spondyloarthritis is dependent on interleukin-23 signaling","volume":"9","author":"Na","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"614255","DOI":"10.3389\/fimmu.2021.614255","article-title":"Why inhibition of IL-23 lacked efficacy in ankylosing spondylitis","volume":"12","author":"McGonagle","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e715","DOI":"10.1016\/S2665-9913(21)00105-3","article-title":"Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: A post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies","volume":"3","author":"Mease","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/rheumatology\/keu237","article-title":"Psoriatic arthritis: Current therapy and future approaches","volume":"54","author":"Huynh","year":"2015","journal-title":"Rheumatology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor family","volume":"9","author":"Gaffen","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.it.2017.01.006","article-title":"IL-17 signaling: The yin and the yang","volume":"38","author":"Amatya","year":"2017","journal-title":"Trends Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/art.38376","article-title":"Interleukin-17+ CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression","volume":"66","author":"Menon","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1002\/art.23655","article-title":"Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides","volume":"58","author":"Jandus","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1084\/jem.194.4.519","article-title":"Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense","volume":"194","author":"Ye","year":"2001","journal-title":"J. Exp. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2005-09-010116","article-title":"An essential role for IL-17 in preventing pathogen-initiated bone destruction: Recruitment of neutrophils to inflamed bone requires IL-17 receptor\u2013dependent signals","volume":"109","author":"Yu","year":"2007","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Blauvelt","year":"2015","journal-title":"J. Am. Acad. Derm."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2014Results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"ref_90","first-page":"890","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: Primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.3899\/jrheum.160275","article-title":"Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: Results from the randomized placebo-controlled FUTURE 2 study","volume":"43","author":"Kavanaugh","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/rheumatology\/kex301","article-title":"Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study","volume":"56","author":"McInnes","year":"2017","journal-title":"Rheumatology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_95","unstructured":"Mease, P., Kavanaugh, A., and Reimold, A. (2016, January 11\u201316). Sustained improvements in the signs and syptoms of active psoriatic arthritis through 3 years: Efficacy and safety results from a phase 3 trial [abstract] 2016 ACR. Proceedings of the ARHP Annual Meeting, Washington, DC, USA."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/acr.23111","article-title":"Secukinumab for long-term treatment of psoriatic arthritis: A two-year followup from a phase iii, randomized, double-blind placebo-controlled study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Care Res."},{"key":"ref_97","first-page":"345","article-title":"THU0411\u2005Secukinumab Efficacy in Anti-TNF-Naive and Anti-TNF-IR Patients with Psoriatic Arthritis: Results of a Phase 3 Multicenter, Double-Blind, Placebo-Controlled Study (Future 2)","volume":"74","author":"Kavanaugh","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/rheumatology\/kez420","article-title":"Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5","volume":"59","author":"Mease","year":"2020","journal-title":"Rheumatology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.bone.2016.01.010","article-title":"Proinflammatory T cells and IL-17 stimulate osteoblast differentiation","volume":"84","author":"Croes","year":"2016","journal-title":"Bone"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13075-018-1582-3","article-title":"IL-17A induces osteoblast differentiation by activating JAK2\/STAT3 in ankylosing spondylitis","volume":"20","author":"Jo","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13075-018-1653-5","article-title":"Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: Results from the prospective PSARTROS study","volume":"20","author":"Kampylafka","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: Results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: Results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","volume":"76","author":"Mease","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/annrheumdis-2020-218808","article-title":"Secukinumab in patients with psoriatic arthritis and axial manifestations: Results from the double-blind, randomised, phase 3 MAXIMISE trial","volume":"80","author":"Baraliakos","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/annrheumdis-2021-eular.1570","article-title":"POS1045\u2005Ixekizumab efficacy on spinal pain, disease activity and quality of life in patients with psoriatic arthritis presenting with symptoms suggestive of axial involvement","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): A double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2019-216835","article-title":"Brodalumab in psoriatic arthritis: Results from the randomised phase III AMVISION-1 and AMVISION-2 trials","volume":"80","author":"Mease","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0001-7310(14)70015-8","article-title":"IL-17 and IL-17R: An auspicious therapeutic target for psoriatic disease","volume":"105","author":"Mitra","year":"2014","journal-title":"Actas Dermo Sifiliogr."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","article-title":"\u03b2-Defensin 2 is a responsive biomarker of IL-17A\u2013driven skin pathology in patients with psoriasis","volume":"139","author":"Kolbinger","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: Evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0140-6736(19)33161-7","article-title":"Bimekizumab in patients with active psoriatic arthritis: Results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial","volume":"395","author":"Ritchlin","year":"2020","journal-title":"Lancet"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: A randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2022","journal-title":"Lancet"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: A randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus Secukinumab in Plaque Psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus Adalimumab in Plaque Psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): Efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/rheumatology\/key070","article-title":"The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis","volume":"58","author":"Veale","year":"2019","journal-title":"Rheumatology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The Janus kinases (Jaks)","volume":"5","author":"Yamaoka","year":"2004","journal-title":"Genome Biol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1146\/annurev-med-051914-021944","article-title":"Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases","volume":"67","author":"Fragoulis","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0952-7915(98)80165-9","article-title":"JAK\/STAT signaling by cytokine receptors","volume":"10","author":"Liu","year":"1998","journal-title":"Curr. Opin. Immunol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S2665-9913(21)00010-2","article-title":"Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: Final analysis of the OPAL Balance long-term extension study","volume":"3","author":"Nash","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): Results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-020-01261-8","article-title":"JAK inhibitors for treatment of psoriasis: Focus on selective TYK2 inhibitors","volume":"80","author":"Nogueira","year":"2020","journal-title":"Drugs"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"eaaw1736","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_131","unstructured":"(2022, December 19). A Study to Determine the Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active Psoriatic Arthritis (PsA) Who Are Na\u00efve to Biologic Disease-Modifying Anti-Rheumatic Drugs, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04908202."},{"key":"ref_132","unstructured":"(2022, December 19). A Study to Determine the Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active Psoriatic Arthritis (PsA) Who Are Na\u00efve to Biologic Disease Modifying Anti-Rheumatic Drugs or Had Previously Received TNF\u03b1 Inhibitor Treatment, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04908189."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/art.39700","article-title":"The Efficacy and Safety of Clazakizumab, an Anti\u2013Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis","volume":"68","author":"Mease","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"151979","DOI":"10.1016\/j.semarthrit.2022.151979","article-title":"Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis\u2014A nationwide cohort study from the DANBIO and DERMBIO registries","volume":"53","author":"Egeberg","year":"2022","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13075-020-02380-z","article-title":"Long-term remission and biologic persistence rates: 12-year real-world data","volume":"23","author":"Murray","year":"2021","journal-title":"Arthritis Res. Ther."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/annrheumdis-2021-220097","article-title":"Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration","volume":"80","author":"Delcoigne","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamadermatol.2022.0364","article-title":"Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database","volume":"158","author":"Penso","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/rheumatology\/key069","article-title":"Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis","volume":"58","author":"Miyagawa","year":"2019","journal-title":"Rheumatology"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial","volume":"81","author":"Kristensen","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial","volume":"81","author":"Papp","year":"2022","journal-title":"Ann. Rheum. Dis."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/7\/6384\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:05:19Z","timestamp":1760123119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/7\/6384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":142,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["ijms24076384"],"URL":"https:\/\/doi.org\/10.3390\/ijms24076384","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,28]]}}}